- Primary endpoint of asthma worsening not met in LEDA Study, however consistent numeric reductions ranging from 32-35% observed across all three GB001 groups - - Statistically significant improvements in key secondary endpoint of time to first asthma worsening of 28% and 30% observed for 20 mg and

- Newly disclosed data build on topline results and continue to support GB004’s differentiated approach of targeting epithelial barrier restoration in patients with ulcerative colitis - - GB004 demonstrated superior barrier protection compared to tofacitinib in pre-clinical human monolayer assay -

SAN DIEGO --(BUSINESS WIRE)--Oct. 9, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will

SAN DIEGO --(BUSINESS WIRE)--Sep. 10, 2020-- Gossamer Bio, Inc.   (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its

SAN DIEGO --(BUSINESS WIRE)--Sep. 7, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will

- GB001: Phase 2 studies, LEDA in eosinophilic asthma and TITAN in chronic rhinosinusitis, on track for topline data readout in the second half of 2020 - - GB002: Expected to commence Phase 2 TORREY study in pulmonary arterial hypertension in the second half of 2020 - - GB004: Expected to commence

SAN DIEGO --(BUSINESS WIRE)--Aug. 5, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will

SAN DIEGO --(BUSINESS WIRE)--Jun. 1, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its participation

SAN DIEGO --(BUSINESS WIRE)--May 29, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the presentation of

SAN DIEGO --(BUSINESS WIRE)--May 19, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the pricing of its